Overview

Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma

Status:
Completed
Trial end date:
2019-11-23
Target enrollment:
0
Participant gender:
All
Summary
Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Michael C Roarke, MD
Treatments:
Fluorodeoxyglucose F18
Criteria
Inclusion Criteria:

- Patients being staged for multiple myeloma as follows: new diagnosis, high risk
smoldering multiple myeloma, relapsed as defined by investigator

- Patients who have undergone standard of care workup

- 300 pounds or less

- Can provide informed consent

- Scheduled for a clinically indicated F-18 FDG PET scan

- English speaking

Exclusion Criteria:

- Pregnant, breast feeding

- Concurrent active non-multiple myeloma malignancy

- Contraindication to PET MRI

- Previous Type I or Type II Diabetes mellitus or a fasting blood glucose >150 mg/dl